Volume | 7,225,238 |
|
|||||
News | - | ||||||
Day High | 9.42 | Low High |
|||||
Day Low | 8.86 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Iovance Biotherapeutics Inc | IOVA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
8.99 | 8.86 | 9.42 | 8.88 | 9.00 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
39,665 | 7,225,238 | US$ 9.03 | US$ 65,235,864 | - | 3.21 - 18.33 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:58:57 | 1 | US$ 8.98 | USD |
Iovance Biotherapeutics (IOVA) Options Flow Summary
Iovance Biotherapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.48B | 279.31M | - | 1.19M | -444.04M | -1.59 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Iovance Biotherapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IOVA Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 10.87 | 10.875 | 8.86 | 9.46 | 6,607,096 | -1.95 | -17.94% |
1 Month | 13.46 | 14.23 | 8.86 | 10.94 | 6,302,519 | -4.54 | -33.73% |
3 Months | 16.834 | 17.14 | 8.86 | 12.62 | 5,641,642 | -7.91 | -47.01% |
6 Months | 5.91 | 18.33 | 5.76 | 11.47 | 8,140,433 | 3.01 | 50.93% |
1 Year | 8.84 | 18.33 | 3.21 | 9.09 | 7,121,456 | 0.08 | 0.90% |
3 Years | 18.59 | 28.00 | 3.21 | 10.27 | 4,469,939 | -9.67 | -52.02% |
5 Years | 18.76 | 54.2081 | 3.21 | 14.21 | 3,369,450 | -9.84 | -52.45% |
Iovance Biotherapeutics Description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. |